Document is current
Any future updates will be listed below
-
Authors
Young, Anthony J.
Doot, Robert K.
Cho, Joshua K.
Pham, Jonathan M.
Ordonez, Alvaro A.
del Castillo, Andres F.
Dominguez, Tiffany L.
Dugyala, Supritha
Schubert, Erin K.
Lee, Hsiaoju
Pantel, Austin R.
Mach, Robert H.
Mankoff, David A.
Sellmyer, Mark A. https://orcid.org/0000-0002-1407-1905
-
Funding
Funding for this research was provided by:
NIH Office of the Director (DP5-OD26386)
National Institute of Biomedical Imaging and Bioengineering (5-T32-EB004311-19)
Intramural Research Program, National Institute on Drug Abuse (K01DA040023)
Burroughs Wellcome Fund (CAMS)
- License Information
-
More Information
Article History
Received: 27 July 2025
Revised: 21 October 2025
Accepted: 23 October 2025
First Online: 22 November 2025
Declarations
:
: Subjects with localized known or suspected infection were recruited and provided informed consent according to guidelines of the University of Pennsylvania Institutional Review Board, and consistent with the ethical standards of the Declaration of Helsinki. Subjects also provided informed consent for publication of their radiographic images. The full study protocols are available at clinicaltrials.gov, NCT03424525 and were performed under the authority of the University of Pennsylvania Radioactive Drug Research Committee.
: M.A.S., D.A.M., and R.H.M. have filed US patent US20180104365A1 assigned to the University of Pennsylvania on radiotracer derivatives of trimethoprim for medical imaging. M.A.S. and R.H.M. hold equity in Vellum Biosciences, a corporate entity which is commercializing TMP radiotracers.
